Karyopharm (KPTI) CAO Kristin Abate Receives Award and Sells Shares

What Happened Kristin Abate, Chief Accounting Officer of Karyopharm Therapeutics (KPTI), had 92 performance-based restricted stock units (PSUs) certified as earned and vested on Jan 27, 2026 and received 92 underlying shares (acquired at $0.00). On Jan 28, 2026 she sold 50 of those shares in a broker-assisted open-market transaction at $7.03 per share, generating $352 — a sale to satisfy tax withholding on the vested PSUs, not an active trading decision.

Key Details

• Transaction dates: PSUs certified and vested/issued on 2026-01-27; sale executed on 2026-01-28; Form 4 filed 2026-01-29.
• Acquisition: 92 shares as the result of earned PSUs, price $0.00 (footnote F1).
• Sale: 50 shares disposed at $7.03 each, total proceeds $352 (footnote F2).
• Reason for sale: Broker-assisted sale pursuant to a durable automatic sale instruction plan to cover withholding taxes — not a discretionary trade by the reporting person (F2).
• Shares owned after transaction: Not specified in this filing.
• Filing timeliness: Form 4 was filed two days after the vesting date (appears timely under Form 4 rules).

Context The 92 shares came from PSUs granted in February 2023 that were performance-based; the Compensation Committee certified achievement of milestones (revenue and TSR) on Jan 27, 2026, and the earned PSUs vested that same day (F1). The small broker-assisted sale (50 shares, $352) was solely to cover tax withholding and is routine; it does not necessarily indicate a change in the insider’s view of the company.